Kim Gyeongmuk, Lee Han-Gyul, Ha Won Jung, Kwon Seungwon
Department of Clinical Korean Medicine, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.
Department of Cardiology and Neurology, Kyung Hee University College of Korean Medicine, Kyung Hee University Medical Center, Seoul 02447, Republic of Korea.
Pharmaceuticals (Basel). 2024 Sep 10;17(9):1192. doi: 10.3390/ph17091192.
BACKGROUND/OBJECTIVES: Anemia is a global health issue affecting diverse populations, particularly older adults, and conventional treatments often show limited efficacy. This study aimed to evaluate the utilization and effectiveness of Sipjeondaebotang (SDT), a prescription drug used in traditional East Asian medicine, in treating various types of anemia.
A scoping review was conducted following Arksey and O'Malley's framework and PRISMA-ScR guidelines. Six electronic databases were searched for clinical studies on SDT, while focusing on human participants and excluding animal and cellular studies. Sixteen studies, including nine randomized controlled trials, two controlled clinical trials, two case series, and three case reports, involving 863 participants, were analyzed. These studies were primarily conducted in China, Korea, and Japan.
According to the analysis, SDT improved hemoglobin levels across all types of anemia studied, with all controlled studies showing significant improvements compared with the control groups. Additionally, SDT reduced blood loss, improved recovery times, and decreased transfusion requirements in patients with post-operative anemia, with lower adverse event rates than those in the control groups. These findings suggest that SDT may enhance hematological parameters and improve overall patient outcomes.
In conclusion, SDT may be an effective treatment for anemia that improves hemoglobin levels and patient outcomes. However, further high-quality, large-scale studies are necessary to standardize SDT prescriptions, confirm the optimal treatment duration, and validate its efficacy and safety across different anemia types.
背景/目的：贫血是一个影响不同人群的全球性健康问题，尤其是老年人，传统治疗方法往往疗效有限。本研究旨在评估东亚传统医学中使用的处方药四君子汤（SDT）在治疗各类贫血中的应用情况及有效性。
按照阿克西和奥马利的框架以及PRISMA-ScR指南进行了一项范围综述。检索了六个电子数据库中关于SDT的临床研究，重点关注人类参与者，排除动物和细胞研究。分析了16项研究，包括9项随机对照试验、2项对照临床试验、2项病例系列研究和3项病例报告，涉及863名参与者。这些研究主要在中国、韩国和日本开展。
根据分析，SDT提高了所研究的各类贫血患者的血红蛋白水平，所有对照研究均显示与对照组相比有显著改善。此外，SDT减少了术后贫血患者的失血，缩短了恢复时间，并降低了输血需求，不良事件发生率低于对照组。这些发现表明SDT可能改善血液学参数并提高患者总体预后。
总之，SDT可能是一种治疗贫血的有效方法，可提高血红蛋白水平和患者预后。然而，需要进一步开展高质量、大规模的研究，以规范SDT的处方，确定最佳治疗疗程，并验证其对不同类型贫血的疗效和安全性。
